Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
19
pubmed:dateCreated
2004-5-18
pubmed:abstractText
Randomized clinical trials have shown that a sirolimus-eluting stent significantly reduces restenosis after percutaneous coronary revascularization. Diabetic patients are known to have a higher risk of restenosis compared with nondiabetic patients. The purpose of this analysis was to determine the impact of sirolimus-eluting stents on outcomes of diabetic compared with nondiabetic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1524-4539
pubmed:author
pubmed:issnType
Electronic
pubmed:day
18
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2273-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:15123524-Aged, pubmed-meshheading:15123524-Anticoagulants, pubmed-meshheading:15123524-Coronary Angiography, pubmed-meshheading:15123524-Coronary Restenosis, pubmed-meshheading:15123524-Coronary Stenosis, pubmed-meshheading:15123524-Diabetes Complications, pubmed-meshheading:15123524-Diabetes Mellitus, pubmed-meshheading:15123524-Disease-Free Survival, pubmed-meshheading:15123524-Double-Blind Method, pubmed-meshheading:15123524-Drug Implants, pubmed-meshheading:15123524-Female, pubmed-meshheading:15123524-Follow-Up Studies, pubmed-meshheading:15123524-Growth Inhibitors, pubmed-meshheading:15123524-Humans, pubmed-meshheading:15123524-Hypertension, pubmed-meshheading:15123524-Immunosuppressive Agents, pubmed-meshheading:15123524-Incidence, pubmed-meshheading:15123524-Insulin, pubmed-meshheading:15123524-Male, pubmed-meshheading:15123524-Middle Aged, pubmed-meshheading:15123524-Mortality, pubmed-meshheading:15123524-Myocardial Infarction, pubmed-meshheading:15123524-Sirolimus, pubmed-meshheading:15123524-Stents, pubmed-meshheading:15123524-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
pubmed:affiliation
Lenox Hill Heart and Vascular Institute and Cardiovascular Research Foundation, 130 East 77th St, 9th Floor, New York, NY 10021, USA. imoussa@lenoxhill.net
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study